Although in general NSAIDs
do not appear to interact with antidiabetics
(see below) azapropazone
and particularly phenylbutazone
seem to cause a consistent lowering of blood glucose levels (probably by inhibiting the metabolism
of the sulphonylureas), which has resulted in severe hypoglycaemia in a number of cases.
Concurrent use with phenylbutazone
should be well monitored and a reduction in the dosage of the sulphonylurea may be necessary to avoid excessive hypoglycae- mia. The manufacturers of azapropazone
say that the concurrent use of sulphonylureas is not recommended.